Filing Flows › Heron Therapeutics (HRTX) › Q2 2026 › vs Q1 2026
Heron Therapeutics (HRTX) Q2 2026 vs Q1 2026 (quarter over quarter)
Heron Therapeutics's revenue rose $3.0M (+9%) from $34.7M in Q1 2026 to $37.7M in Q2 2026. The biggest changes: CINVANTI +$1.3M (+6%); Aponvie +$883K (+26%); ZYNRELEF +$821K (+8%).
Heron Therapeutics, Q2 2026: revenue $37.7M (+1% year over year), operating margin -5.4%, net loss $5.5M, operating cash flow −$2.2M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| CINVANTI | $21.8M | $20.5M | $1.3M | +6% |
| ZYNRELEF | $11.1M | $10.2M | $821K | +8% |
| Aponvie | $4.3M | $3.4M | $883K | +26% |
| SUSTOL | $540K | $547K | −$7K | -1% |
| Revenue | $37.7M | $34.7M | $3.0M | +9% |
| Net loss | $5.5M | $8.1M | −$2.6M | -32% |
| Costs & expenses | $43.2M | $42.8M | $333K | +0.8% |
| Operating costs | $39.7M | $39.5M | $234K | +0.6% |
| Interest & other, net | $3.4M | $3.3M | $99K | +3% |
| Cost of revenue | $11.6M | $10.6M | $934K | +9% |
| Research & development | $2.7M | $2.4M | $317K | +13% |
| Sales & marketing | $14.2M | $14.3M | −$148K | -1% |
| General & admin | $11.3M | $12.1M | −$869K | -7% |
| Operating cash sources | $5.8M | $5.0M | $798K | +16% |
| Depreciation & amortization | $452K | $529K | −$77K | -15% |
| Share-based compensation | $3.2M | $3.0M | $202K | +7% |
| Cash used in operations | $2.2M | $1.5M | $673K | +44% |
| Net loss absorbed | $5.5M | $8.1M | −$2.6M | -32% |
| Working capital & other | $354K | −$3.1M | $3.4M | — |
Questions
How much did Heron Therapeutics's revenue grow quarter over quarter in Q2 2026?
Heron Therapeutics's revenue rose $3.0M (+9%) from $34.7M in Q1 2026 to $37.7M in Q2 2026.
What drove Heron Therapeutics's revenue change in Q2 2026?
CINVANTI +$1.3M (+6%); Aponvie +$883K (+26%); ZYNRELEF +$821K (+8%).